The research of Dr. Sévigny’s team focusses on the functions of extracellular nucleotides, exerted through the activation of P2 receptors, with an emphasis on the enzymes that regulate their concentrations at the cell surface.  Dr. Sévigny and his team have also identified, cloned and characterized six new genes, including the first member of a new family encoding enzymes called NTPDases.  His team is interested in several biological functions including the regulation of inflammation in response to pathogenic determinants, the migration of immune cells, the functions of leukocytes, the contraction of smooth muscles, and in particular the regulation of inflammation of the intestine with an emphasis on epithelial cells and on a potential treatment for inflammatory bowel disease.

Dr Sévigny’s team uses animal models with KO mice as well as methods of cell biology (murine and human primary cells), pharmacology, biochemistry and immunology.

CHUL
2705, boulevard Laurier
T1-49
Québec, Québec
Canada G1V 4G2
303 entries « 31 of 31 »

Sévigny J, Côté YP, Beaudoin AR

Purification of pancreas type-I ATP diphosphohydrolase and identification by affinity labelling with the 5'-p-fluorosulphonylbenzoyladenosine ATP analogue

Journal Article

Biochem J, 312 ( Pt 2) , 1995.

Abstract | Links:

Sévigny J, Beaudoin AR

Le monde des nucléotides extracellulaires

Journal Article

Med Sci (Paris), 10 (8-9), 1994.

Bélanger A, Locong A, Noel C, Cusan L, Dupont A, Prévost J, Caron S, Sévigny J

Influence of diet on plasma steroids and sex hormone-binding globulin levels in adult men

Journal Article

J Steroid Biochem, 32 (6), 1989.

Abstract | Links:

303 entries « 31 of 31 »
Signaler des ajouts ou des modifications

Active projects

  • A recombinant soluble NTPDase8 as a novel biological treatment for inflammatory bowel disease, from 2021-10-01 to 2026-09-30
  • Ectonucleotidases and Extracellular Nucleotides in Smooth Muscle Cell Contraction, from 2023-04-01 to 2028-03-31
  • Novel P2Y6 antagonists as a potential therapy for inflammatory bowel disease, from 2021-07-01 to 2025-06-30
  • Regroupement Québécois de Recherche sur la Fonction, l’Ingénierie et les Applications des Protéines, from 2024-04-01 to 2030-03-31

Recently finished projects

  • A novel approach to treating inflammatory bowel diseases through the blocking of P2Y6 receptors, from 2018-04-01 to 2023-03-31
  • Scaling up the production of recombinant human NTPDase8 in CHO expression system for in vivo testing, from 2023-09-01 to 2024-03-31
Data provided by the Université Laval research projects registery